Clinical Trial

High-energy Human Milk Diets in the First Two Weeks After Birth to Reduce BPD in Extremely Preterm Infants

Study acronym: MEND-BPD
Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This Phase II, parallel-group, masked, randomized clinical trial aims to evaluate whether a DHA/ARA-enriched, fortified human milk diet administered during the first 14 days of life reduces respiratory morbidity and improves lung function in extremely preterm (EPT) infants (born at ≤28 weeks gestation).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-26.
Trial Details
NCT Number NCT07307612
Lead Sponsor University of Alabama at Birmingham
Collaborators: National Heart, Lung, and Blood Institute (NHLBI)
Conditions Extreme Prematurity, Enteral Nutrition, Bronchopulmonary Dysplasia
Enrollment 150 participants
Start Date 2026-08-15
Primary Completion 2029-03-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-12